E Bargagli1, C Piccioli2, E Rosi2, E Torricelli2, L Turi2, E Piccioli2, M Pistolesi2, K Ferrari2, L Voltolini3. 1. Department of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, Italy. Electronic address: bargagli2@gmail.com. 2. Department of Clinical and Experimental Medicine, University Hospital Careggi, Largo Brambilla 1, 50134 Florence, Italy. 3. Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla 1, 50134 Florence, Italy.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2-5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectiveness of Pirfenidone and Nintedanib in a population of IPF patients diagnosed in the last 12 months at Florence ILD Referral Centre. METHODS: In the last 12 months, 82 IPF patients (66 male, mean age 78.3±23.8 years) were diagnosed and started antifibrotic therapy with Pirfenidone or Nintedanib. Their clinical and functional details were analyzed retrospectively at time 0 and after 6 and 12 months of therapy. RESULTS: The median age of the patients treated with Nintedanib was higher than that of the Pirfenidone group (p<0.0001). The most common symptoms at disease onset were exertional dyspnoea and dry cough with no differences between the two groups (p<0.05). All IPF patients manifested bibasal crackles at the time of diagnosis. No significant differences in FVC, FEV1, TLC and DLCO were found at time 0 or after 6 months between patients treated with Pirfenidone and Nintedanib (p>0.05). After 1 year, lung function test parameters of patients treated with Pirfenidone had remained stable from baseline. DISCUSSION: This study emphasizes that both antifibrotic drugs appeared to be a good therapeutic choice in terms of functional stabilization, also in older patients. Published by Elsevier España, S.L.U.
BACKGROUND:Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2-5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectiveness of Pirfenidone and Nintedanib in a population of IPFpatients diagnosed in the last 12 months at Florence ILD Referral Centre. METHODS: In the last 12 months, 82 IPFpatients (66 male, mean age 78.3±23.8 years) were diagnosed and started antifibrotic therapy with Pirfenidone or Nintedanib. Their clinical and functional details were analyzed retrospectively at time 0 and after 6 and 12 months of therapy. RESULTS: The median age of the patients treated with Nintedanib was higher than that of the Pirfenidone group (p<0.0001). The most common symptoms at disease onset were exertional dyspnoea and dry cough with no differences between the two groups (p<0.05). All IPFpatients manifested bibasal crackles at the time of diagnosis. No significant differences in FVC, FEV1, TLC and DLCO were found at time 0 or after 6 months between patients treated with Pirfenidone and Nintedanib (p>0.05). After 1 year, lung function test parameters of patients treated with Pirfenidone had remained stable from baseline. DISCUSSION: This study emphasizes that both antifibrotic drugs appeared to be a good therapeutic choice in terms of functional stabilization, also in older patients. Published by Elsevier España, S.L.U.
Authors: Paolo Cameli; Rosa Metella Refini; Laura Bergantini; Miriana d'Alessandro; Valerio Alonzi; Carlo Magnoni; Paola Rottoli; Piersante Sestini; Elena Bargagli Journal: Front Mol Biosci Date: 2020-09-04
Authors: Lucia Vietri; Paolo Cameli; Marco Perruzza; Behar Cekorja; Laura Bergantini; Miriana d'Alessandro; Rosa Metella Refini; Maria Pieroni; Antonella Fossi; David Bennett; Marco Spalletti; Maria Antonietta Mazzei; Piersante Sestini; Paola Rottoli; Elena Bargagli Journal: Ther Adv Respir Dis Date: 2020 Jan-Dec Impact factor: 4.031
Authors: Colin H Holtze; Elizabeth A Freiheit; Susan L Limb; John L Stauffer; Karina Raimundo; Wayne T Pan; Kevin R Flaherty; Hyun J Kim Journal: Respir Res Date: 2020-02-10
Authors: Claudia Valenzuela; Sebastiano Emanuele Torrisi; Nicolas Kahn; Manuel Quaresma; Susanne Stowasser; Michael Kreuter Journal: Respir Res Date: 2020-01-06